The metabolic syndrome (MetSyn) is a high-risk phenotype characterized by the combination of cardiometabolic risk factors, including obesity, dyslipidemia, hypertension, impaired fasting glucose, proinflammatory state, and a prothrombotic state.[@bib1] First described by Reaven,[@bib2] MetSyn is believed to be a common physiologic predecessor for chronic diseases including cardiovascular disease,[@bib3], [@bib4], [@bib5] type 2 diabetes mellitus,[@bib6] and premature mortality.[@bib4], [@bib7] Defining criteria for MetSyn have been established by multiple agencies over time,[@bib1], [@bib8], [@bib9], [@bib10], [@bib11] but the most frequently used are those published by the National Cholesterol Education Program (NCEP)/Adult Treatment Panel[@bib12] and the International Diabetes Foundation.[@bib9], [@bib11] The prevalence of MetSyn has varied as a function of the defining criteria,[@bib13] but it has been reported to exist in one-fourth to one-third of adults in the United States.[@bib13], [@bib14], [@bib15], [@bib16] Moreover, the prevalence appears to be on the rise,[@bib14], [@bib15], [@bib16] particularly in women,[@bib14], [@bib15], [@bib16] and with advancing age, with the greatest prevalence seen in adults 60 years or older.[@bib14] When combining the adverse consequences associated with MetSyn with its continuing rise in prevalence, it seems clear that MetSyn will continue to represent a serious public health issue well into the future.

Low cardiorespiratory fitness (CRF) has been associated with the presence of metabolic risk factor clustering and MetSyn in numerous published studies.[@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31] However, the defining criteria for MetSyn, the assessment of CRF, and the specific cohort characteristics have varied considerably among these studies. Variations in any one or all the above parameters could influence the overall study findings and the generalizability of the results. Early reports used higher thresholds for impaired fasting blood glucose (≥110 mg/dL \[to convert to mmol/L, multiply by 0.0555\]),[@bib18], [@bib21], [@bib23], [@bib26], [@bib27], [@bib28], [@bib31] hypertension (blood pressure ≥140/90 mm Hg),[@bib18], [@bib27], [@bib31] and/or varying measures/thresholds for abdominal obesity,[@bib17], [@bib18], [@bib27], [@bib31] which were more consistent with the defining criteria for MetSyn at the time. Other studies used population- and/or country-specific definitions for abdominal obesity.[@bib17], [@bib24], [@bib28], [@bib30] Only 3 recent reports incorporated the current MetSyn risk factor criteria for each of the 5 common markers---including drug treatment for hypertension, dyslipidemia, and/or elevated fasting glucose as a qualifying factor.[@bib25], [@bib29], [@bib30] Of these, 2 of the studies included only older[@bib30] or only younger[@bib29] adults, and only 1 study included women.[@bib30]

In light of the recent public health recommendation to include assessment of CRF in medical examinations[@bib32] and the advocacy for inclusion of cardiopulmonary exercise testing (CPX),[@bib33], [@bib34] more information from studies in which CRF was directly measured may aid clinicians in the evaluation and treatment of multiple chronic diseases (eg, cardiovascular disease and heart failure). Most of the published studies on MetSyn incorporated a CRF level estimated from a maximal exercise test,[@bib17], [@bib19], [@bib21], [@bib22], [@bib23], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31] which has been associated with an estimation error of between 1 and 2 metabolic equivalents. Only 5 of the published studies on MetSyn used CPX-derived maximal oxygen uptake (VO~2max~)[@bib23], [@bib27], [@bib28], [@bib29], [@bib30] to define CRF. Two of these studies used leg cycling as the mode of exercise, which is associated with 10% to 20% lower measured oxygen uptake as compared with treadmill testing.[@bib23], [@bib27], [@bib35] Four of the 5 studies incorporated solely older[@bib23], [@bib30] or younger[@bib28], [@bib29] adults, which would not be as generalizable across a wide age spectrum. Furthermore, only 2 of the studies in which CRF was defined using measured VO~2max~ included women, and these 2 cohorts collectively represented approximately 1171 older women.[@bib23], [@bib30] When combining the limited number of participants within these studies with the sex and/or age delimitations, the VO~2max~ thresholds associated with increased risk for MetSyn in middle-aged adults are less clear. Therefore, additional information from studies that include (1) contemporary risk factor thresholds, (2) a large sample and broad age range of men and women, and (3) VO~2max~ determined with CPX is needed to refine the understanding of the association between CRF and MetSyn.

The purpose of the present investigation was to assess the association between directly measured CRF (VO~2max~) and metabolic risk factor clustering in a broad age range of men and women using current MetSyn risk factor criteria.

Participants and Methods {#sec1}
========================

Study Population and Design {#sec1.1}
---------------------------

Participants completed laboratory assessments through the [B]{.ul}all State [A]{.ul}dult Fitness Program [L]{.ul}ongitudinal [L]{.ul}ifestyle [ST]{.ul}udy (BALL ST), which is an ongoing population-based program initiated in 1970 to promote healthy lifestyles and physical fitness. This retrospective cross-sectional analysis included 3636 self-referred adult males and females (aged 19-95 years) who completed a physical examination including maximal exercise testing with respiratory gas analysis (CPX) within the BALL ST between the years January 1, 1971, and November 1, 2016. Deidentified data were exported from the BALL ST longitudinal database. Inclusion criteria consisted of being 18 years or older, having complete data for all MetSyn risk markers (see below), and attainment of greater than or equal to 1.0 respiratory exchange ratio during the maximal exercise test. For individuals with multiple test records, the first test with complete data for all relevant MetSyn risk markers was used. All data were deidentified, and participants provided written informed consent for their information to be used for research. Ball State University (BSU) Institutional Review Board approved all data collection procedures and determined the study "exempt" because of the use of deidentified data.

Clinical Measurements {#sec1.2}
---------------------

All participants were instructed to refrain from exercise, caffeine, and alcohol for 12 hours before testing and arrive on the initial day of testing in a fasting state. They were also instructed to continue their regular medication routines. Participants completed a health history questionnaire, which provided self-reported information about medical history, lifestyle habits (eg, smoking, physical activity, and diet), and medications.[@bib36] Each participant then completed a series of assessments including anthropometric measurements (height, weight, and waist and hip circumferences), body composition, resting heart rate and blood pressure, blood chemistry, and resting 12-lead electrocardiography. Standardized laboratory techniques were used for all resting assessments and have been described in detail elsewhere.[@bib36], [@bib37], [@bib38]

Metabolic Markers {#sec1.3}
-----------------

Metabolic syndrome markers and their thresholds were defined according to the NCEP.[@bib1], [@bib8] Markers and thresholds included central obesity (waist circumference ≥102 cm for men or ≥88 cm for women), elevated fasting plasma triglycerides (≥150 mg/dL; to convert to mmol/L, multiply by 0.0113), low high-density lipoprotein cholesterol (HDL-C; \<40 mg/dL for men or \<50 mg/dL for women; to convert to mmol/L, multiply by 0.0259), elevated fasting plasma glucose (≥100 mg/dL), hypertension (blood pressure ≥130 mm Hg systolic or 85 mm Hg diastolic), or pharmacologic treatment for diagnosed hypertension, hypertriglyceridemia, low HDL-C, or diabetes. Waist girth was taken in the horizontal plane at the smallest circumference in the abdominal region, generally 2 to 4 in above the umbilicus. Plasma lipids were measured after a 12-hour fast, and resting blood pressure values were measured in the seated position after a 5-minute rest period. A minimum of 2 blood pressure measurements were recorded, with additional measurement taken if the initial 2 differed by more than 6/4 mm Hg for systolic or diastolic, respectively. Participants reporting medication use for treatment of hypertriglyceridemia or low HDL-C were classified as positive for these metabolic markers.[@bib8], [@bib11] The presence of the metabolic syndrome was defined as meeting the criteria for 3 or more of the metabolic markers.[@bib8]

Exercise Testing and CRF {#sec1.4}
------------------------

All participants completed a maximal CPX on a treadmill as part of their physical examination. Exercise test protocols varied and included Bruce,[@bib39] Ball State University Bruce Ramp,[@bib40] modified Balke,[@bib41] or other nonspecified protocols. In most cases, selection of test protocol was individualized on the basis of participant characteristics, with a goal to achieve maximal effort within 8 to 12 minutes. Exercise heart rate was measured using electrocardiography (single-lead or 12-lead, depending on date) and recorded each minute at peak exercise and during recovery from the exercise test. Exercise blood pressures were monitored manually during exercise and recovery. Gas exchange data were collected using open circuit spirometry with methods described previously.[@bib36] Standardized procedures for metabolic cart calibration were followed for all tests, and tests were supervised by clinical exercise physiologists, with additional medical supervision when appropriate.[@bib42] Participants were verbally encouraged to exercise to volitional fatigue. Cardiorespiratory fitness was indicated by VO~2max~, defined as the average of 2 or 3 consecutive VO~2~ values within 2 mL per kg/minute, occurring in the last 2 minutes of the CPX.

Statistical Analyses {#sec1.5}
--------------------

Descriptive statistics were computed for all study variables and are presented in [Table 1](#tbl1){ref-type="table"}. For analyses purposes, cigarette smoking was characterized as current smoker, former smoker, or never smoked, and physical activity was characterized as regularly active in endurance exercise (≥3 sessions per week of running, walking, swimming, and/or cycling) or not. Differences in participant characteristics and metabolic markers between those with and without the MetSyn were tested for statistical significance with Student *t* test or the *χ*^*2*^ test where indicated.Table 1Defining Characteristics of the BALL ST Cohort[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}CharacteristicMen (n=2007)Women (n=1629)Total (n=3636)Age (y)[d](#tbl1fnd){ref-type="table-fn"}45.0±11.944.2±12.744.7±12.3Current smoking (%)[d](#tbl1fnd){ref-type="table-fn"}13.98.811.6BMI (kg/m^2^)[d](#tbl1fnd){ref-type="table-fn"}27.7±5.027.0±6.327.4±5.6Waist circumference (cm)[d](#tbl1fnd){ref-type="table-fn"}96.1±13.382.8±14.490.1±15.3Resting SBP (mm Hg)[d](#tbl1fnd){ref-type="table-fn"}126±15118±15122±15Resting DBP (mm Hg)[d](#tbl1fnd){ref-type="table-fn"}81±1075±1079±10Total cholesterol (mg/dL)[d](#tbl1fnd){ref-type="table-fn"}208.4±45.5200.4±40.6204.8±43.4LDL-C (mg/dL)[d](#tbl1fnd){ref-type="table-fn"}130.7±37.9118.3±35.2124.9±37.2HDL-C (mg/dL)[d](#tbl1fnd){ref-type="table-fn"}45.7±12.458.0±15.251.4±15.1Triglycerides (mg/dL)[d](#tbl1fnd){ref-type="table-fn"}146.8±120.6116.3±73.0134.8±103.2Fasting glucose (mg/dL)98.6±22.993.8±19.096.5±21.4Physically active (%)[d](#tbl1fnd){ref-type="table-fn"}32.523.128.2Resting HR (beats/min)[d](#tbl1fnd){ref-type="table-fn"}67±11.570±10.068±11.0Maximal HR (beats/min)176±17.6175±16.4175±17.0VO~2max~ (mL/kg/min)[d](#tbl1fnd){ref-type="table-fn"}36.2±10.327.5±8.032.2±10.3FRIEND percentile[d](#tbl1fnd){ref-type="table-fn"}44±27.048±26.045±27.0[^1][^2][^3][^4]

Several methods were used to assess the association between CRF and MetSyn. First, CRF was used as a continuous scale variable in analyses (mL/kg per minute) and the age- and sex-adjusted difference in CRF was computed between those with and without MetSyn. Second, sex-stratified CRF quartiles were created and logistic regression models were computed using the lowest fitness quartile as the reference group. Finally, as a complementary approach to assessing the relationship between CRF and MetSyn, an individual\'s VO~2max~ was converted to an age- and sex-specific percentile score using the reference values from the Fitness Registry and the Importance of Exercise National Database (FRIEND).[@bib34] For analysis, participants were stratified into lowest VO~2max~ (Q1 ≤25th percentile), Q2 was 26th to 50th percentile, Q3 was 51st to 75th percentile, and highest VO~2max~ (Q4 \>75th percentile) of the FRIEND. Odds ratios were computed for the FRIEND quartiles using the lowest fitness category (Q1) as the reference group.

All analyses were performed using SPSS version 24 and SAS version 9.3. A *P* value of less than .01 was considered statistically significant.

Results {#sec2}
=======

The prevalence of each of the metabolic markers of the MetSyn is presented in [Table 2](#tbl2){ref-type="table"}. Hypertension was the most frequent risk factor, followed by impaired fasting blood glucose, and then the others. The proportion of the cohort with clustering of one or more metabolic markers is presented in [Table 3](#tbl3){ref-type="table"}. Within this cohort, the presence of MetSyn as defined by having 3 or more risk factors was 26% (953 of 3636). Men were more likely to have each of the associated risk factors and MetSyn than women (30% vs 21%) (*P*\<.001). Those with MetSyn were also older, less physically active, and had lower maximal heart rate and VO~2max~ compared with those who were free of the syndrome (*P*\<.001). Those within the cohort who had MetSyn had a VO~2max~ value of 7.8 (7.1-8.5) mL/kg per minute lower than did those without MetSyn. After adjusting for age and sex in the model, those with MetSyn had a CRF value of 7.2 (6.6-7.7) mL/kg per minute lower than did those without MetSyn ([Table 4](#tbl4){ref-type="table"}).Table 2Prevalence of Metabolic Syndrome Risk Factors[a](#tbl2fna){ref-type="table-fn"}Risk factorMen (n=2007)Women (n=1629)Combined (N=3636)Waist circumference[b](#tbl2fnb){ref-type="table-fn"}28.1% (564)31.7% (516)29.7% (1080)Impaired fasting glucose[c](#tbl2fnc){ref-type="table-fn"}37.2% (746)23.6% (385)36.1% (1311)Hypertension[d](#tbl2fnd){ref-type="table-fn"}52.3% (1049)32.9% (536)43.6% (1585)HDL-C[e](#tbl2fne){ref-type="table-fn"}29.2% (586)28.5% (464)28.9% (1050)Triglycerides[f](#tbl2fnf){ref-type="table-fn"}34.2% (686)21.2% (345)28.4% (1031)[^5][^6][^7][^8][^9][^10]Table 3Clustering of Metabolic Syndrome Risk FactorsNo. of risk factors meeting thresholdMen (n=2007)Women (n=1629)Combined (N=3636)020.0% (403)32.9% (537)25.9% (940)126.4% (529)29.0% (479)27.7% (1008)223.3% (467)16.5% (268)20.2% (735)3[a](#tbl3fna){ref-type="table-fn"}17.0% (341)12.0% (195)14.7% (536)4[a](#tbl3fna){ref-type="table-fn"}9.5% (190)6.4% (104)8.1% (294)5[a](#tbl3fna){ref-type="table-fn"}3.8% (77)2.8% (46)3.4% (123)[^11]Table 4Defining Characteristics---MetSyn Compared With Apparently Healthy Individuals[a](#tbl4fna){ref-type="table-fn"}^,^[b](#tbl4fnb){ref-type="table-fn"}^,^[c](#tbl4fnc){ref-type="table-fn"}CharacteristicMetSyn (n=953)No MetSyn (n=2683)Age (y)[d](#tbl4fnd){ref-type="table-fn"}48.3±11.843.4±12.2Current smoking (%)11.511.6BMI (kg/m^2^)[d](#tbl4fnd){ref-type="table-fn"}32.3±5.025.6±6.3Waist circumference (cm)[d](#tbl4fnd){ref-type="table-fn"}104.5±13.685.0±12.3Resting SBP (mm Hg)[d](#tbl4fnd){ref-type="table-fn"}132±16119±14Resting DBP (mm Hg)[d](#tbl4fnd){ref-type="table-fn"}85±1077±10Total cholesterol (mg/dL)[d](#tbl4fnd){ref-type="table-fn"}213.2±48.4201.9±41.1LDL-C (mg/dL)[d](#tbl4fnd){ref-type="table-fn"}129.7±38.2123.2±36.7HDL-C (mg/dL)[d](#tbl4fnd){ref-type="table-fn"}45.7±12.458.0±15.2Triglycerides (mg/dL)[d](#tbl4fnd){ref-type="table-fn"}146.8±120.6116.3±73.0Fasting blood glucose (mg/dL)[d](#tbl4fnd){ref-type="table-fn"}110.0±31.691.7±13.3Physically active (%)[d](#tbl4fnd){ref-type="table-fn"}15.233.2Resting HR (beats/min)[d](#tbl4fnd){ref-type="table-fn"}72±10.667±10.8Maximal HR (beats/min)[d](#tbl4fnd){ref-type="table-fn"}169±19.2178±15.6VO~2max~ (mL/kg/min)[d](#tbl4fnd){ref-type="table-fn"}26.6±7.134.3±10.5FRIEND percentile[d](#tbl4fnd){ref-type="table-fn"}28±20.052±26.0[^12][^13][^14][^15]

Results from the logistic regression based on the cohort analyses are presented in [Tables 5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"}. They show a statistically significant inverse and graded association between VO~2max~ and the prevalence of MetSyn for the group overall (*P*\<.001) and for the men and women separately (*P*\<.001). In the analysis that included all participants (n=3636), the association was statistically significant after adjusting for age and sex (*P*\<.001), and the prevalence of MetSyn ranged from 53.3% in the lowest-fit quartile (Q1) to 3.0% in the most-fit quartile (Q4). The most-fit quartile was more than 20 times less likely to have MetSyn compared with their least-fit counterparts, and the association showed a graded response, with the middle 2 quartiles also significantly less likely to have the MetSyn than the least-fit quartile (*P*\<.01). This relationship was also shown for men and women, respectively.Table 5Prevalence and Cohort Logistic Regression Models for MetSyn[a](#tbl5fna){ref-type="table-fn"}^,^[b](#tbl5fnb){ref-type="table-fn"}ModelLowest-fit quartileQuartile 2Quartile 3Highest-fit quartileN=MetSyn484 (53.3%)294 (32.4%)148 (16.3%)27 (3.0%) OR1.00.67 (0.55-0.81)0.41 (0.34-0.51)0.10 (0.07-0.14) OR[c](#tbl5fnc){ref-type="table-fn"}1.00.49 (0.40-0.60)0.30 (0.34-0.38)0.07 (0.05-0.10) OR[d](#tbl5fnd){ref-type="table-fn"}1.00.29 (0.23-0.37)0.13 (0.10-0.17)0.03 (0.02-0.04)[^16][^17][^18][^19]Table 6Prevalence and Sex-Specific Cohort Logistic Regression Models for MetSyn[a](#tbl6fna){ref-type="table-fn"}^,^[b](#tbl6fnb){ref-type="table-fn"}ModelLowest-it quartileQuartile 2Quartile 3Highest-fit quartileWomen N=MetSyn192 (47.2%)97 (23.8%)53 (13.0%)3 (0.7%) VO~2max~ (mL/kg/min)≤21.521.6-26.126.2-31.7≥31.8 OR1.00.25 (0.18-0.34)0.05 (0.02-0.10)0.02 (0.01-0.09) OR[c](#tbl6fnc){ref-type="table-fn"}1.00.26 (0.19-0.36)0.05 (0.03-0.12)0.03 (0.01-0.13)Men N=MetSyn292 (58.3%)197 (39.2%)95 (18.9%)24 (4.8%) VO~2max~ (mL/kg/min)≤28.728.8-35.135.2-42.6≥42.7 OR1.00.43 (0.31-0.59)0.19 (0.14-0.27)0.03 (0.02-0.05) OR[c](#tbl6fnc){ref-type="table-fn"}1.00.39 (0.27-0.55)0.16 (0.11-0.24)0.03 (0.02-0.05)[^20][^21][^22]

Those with MetSyn had a VO~2max~ percentile from the FRIEND of 28±20 percentile as opposed to those without the syndrome who averaged a VO~2max~ percentile of 52±26 (*P*\<.001). The logistic regression results for the analysis that incorporated the FRIEND version of CRF for the women and men are presented in [Table 7](#tbl7){ref-type="table"} and also show a significant inverse gradient for MetSyn and VO~2max~ (*P*\<.01). The results remain significant after adjusting for age in the logistic regression models.Table 7Prevalence and Logistic Regression Models for MetSyn Using the FRIEND Percentiles[a](#tbl7fna){ref-type="table-fn"}^,^[b](#tbl7fnb){ref-type="table-fn"}ModelLowest-fit FRIEND\
≤25th percentileQuartile 2\
26th-50th percentileQuartile 3\
51st-75th percentileHighest-fit FRIEND\
≥76th percentileWomen with MetSyn179 (43.2%)95 (20.6%)53 (12.6%)18 (5.4%) Odds ratio1.00.36 (0.26-0.49)0.19 (0.13-0.30)0.07 (0.04-0.13)Men with MetSyn357 (54.6%)169 (29.4%)64 (14.4%)18 (5.4%) Odds ratio1.00.31 (0.24-0.40)0.13 (0.09-0.18)0.06 (0.04-0.09)[^23][^24]

Discussion {#sec3}
==========

The major finding of this study was the significant inverse association between VO~2max~ and MetSyn, with the most physically fit individuals (upper quartile) being more than 20 times less likely to have MetSyn compared with the least-fit individuals. The difference in VO~2max~ between those individuals with MetSyn and those without was approximately 2.5 metabolic equivalents. The association between VO~2max~ and MetSyn was also graded across the range of fitness scores within our cohort, with the 2 middle groups having intermediate prevalence rates ([Tables 5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"}). This relationship remained significant and was strengthened by adjusting for age and sex in the models. This large cohort of men and women had a broad range of scores for age, VO~2max~, and the risk factors for MetSyn.

Although these findings are generally consistent with previous studies,[@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib23], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31] our results are based on *current* risk factor thresholds for MetSyn,[@bib1], [@bib8] represent the largest cohort with directly measured VO~2max~ of the available studies, and incorporate the FRIEND percentiles into our analysis.[@bib34] Our results demonstrate that a lower VO~2max~ (or lower VO~2max~ percentile from FRIEND) is associated with a greater prevalence of MetSyn in both men and women, and based on the analyses deployed, our results are graded in nature.

Only a handful of studies of CRF and MetSyn[@bib20], [@bib25], [@bib29] have used the current risk factor thresholds defined by the NCEP/Adult Treatment Panel,[@bib1], [@bib8] which is most likely due to the modifications in the risk factor thresholds over time. Nonetheless, these modifications increase the number of individuals classified as having MetSyn. Considering only those studies that used the current risk factor thresholds, Ekblom et al[@bib20] studied approximately 686 men and women and quantified CRF using a submaximal cycling test. They did not measure VO~2max~ in their study, but using the current thresholds did report that the sex-adjusted high-fit group was less likely to have MetSyn. Misigoj-Durakovic et al[@bib29] studied 577 younger men (mean age, 30 years) and used a maximal treadmill test with measured VO~2max~. These authors reported higher odds ratios for the upper 3 CRF quartiles (0.42, 0.38, and 0.10) when using the least-fit quartile as the reference group compared with the present study (0.37, 0.16, and 0.02 for men). Their study was in younger men, so direct comparisons of results are not prudent, but our findings suggest a stronger graded relationship in men and add women to these findings. Finally, Ingle et al[@bib25] studied a much larger sample of men (∼9666) compared with the present study but used a submaximal treadmill test to assess CRF and reported only 2 categories of men, *unfit* vs *fit*. Although their higher *fit* men were less likely to have clustering of the risk factors, their odds ratio of 0.51 for the *fit* men is not directly comparable to that in the present study. Our results, using the criterion standard (eg, measured VO~2max~), represent a stronger study design compared with these reports.

Our study results are novel for the inclusion of measured VO~2max~ as the measure of CRF in a cohort of men and women with a broad age range. Most published studies[@bib17], [@bib19], [@bib21], [@bib22], [@bib23], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31] incorporated a maximal exercise test for assessment of CRF, but of these, only 5 used directly measured VO~2max~ as the measure of CRF.[@bib23], [@bib27], [@bib28], [@bib29], [@bib30] Lakka et al[@bib27] and Hassinen et al[@bib23] reported results where VO~2max~ was quantified using a cycle ergometer test, whereas Lee et al,[@bib28] Misigoj-Durakovic et al,[@bib29] and Sandbakk et al[@bib30] deployed a maximal treadmill test. Although all the studies reported a significant inverse association between VO~2max~ and the prevalence of MetSyn, the studies most comparable to the present one are those measuring VO~2max~ using a motorized *treadmill* protocol. Lee et al[@bib28] assessed 909 young men (age, 24±2 years) who had a much higher CRF, and the risk factor thresholds for waist circumference and fasting blood glucose were not the same as in the present study. Nonetheless, they reported that the middle and high fitness tertiles had a significantly lower risk for MetSyn. Sandbakk et al[@bib30] studied older men and women (aged 70-77 years) and reported that high CRF was associated with a lower risk for MetSyn. However, their risk thresholds for waist girth were lower than in the present study and the present study included a much wider range of age and CRF. Finally, Misigoj-Durakovic et al[@bib29] assessed a smaller group of younger men (577; age, 19-47 years) and as stated above, their results for the highest fitness group of men were similar to those of the present study. Based on these available studies that defined CRF measured with CPX and treadmill exercise, our results represent the association with a much broader age range of both men and women.

Although multiple studies included women[@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib30], [@bib31] and show the inverse association between a measure of CRF and MetSyn, the present study represents the largest group of women that used a measured VO~2max~ to define CRF. Four of the studies that included women were from the same cohort[@bib19], [@bib21], [@bib22], [@bib31] and defined CRF with a maximal exercise test without CPX. Although they reported an inverse association between CRF and MetSyn for women, they reported much lower overall prevalence rates for MetSyn compared with the present study (6.5% and 4.2% vs 21%). Differences in prevalence rates are partly due to a difference in the risk factor thresholds used compared with the present study (fasting blood glucose, ≥110 mg/dL vs ≥100 mg/dL), but could also be due to other factors such as sampling differences. The number of women with each metabolic risk factor was significantly lower in the study by Farrell et al[@bib21] compared with the present study, and the other study is from the same cohort.

There are 2 studies that incorporated VO~2max~ as the measure of CRF in women.[@bib23], [@bib30] Although these studies used slightly different risk factor thresholds and represented much older women (Sandbakk et al[@bib30]: age, 70-77 years; Hassinen et al[@bib23]: age, 65±5 years), they do represent studies with a measured VO~2max~. Both these studies used tertiles of VO~2max~ in their analyses, and the lowest-fit women were significantly more likely to have MetSyn compared with the highest-fit women in their respective analyses. The present study represents a significantly larger sample of women and also represents a much wider age *range* compared with these previous studies that defined CRF with VO~2max~. Therefore, our results extend the findings of these previous reports to a much broader age range of women.

This is the first study to incorporate the FRIEND database values for CRF into analyses[@bib34] ([Table 7](#tbl7){ref-type="table"}). Each participant in the present study had their VO~2max~ converted into a sex- and age-adjusted FRIEND percentile, and then this value was used in the logistic regression model as opposed to their actual VO~2max~ value. Both men and women showed significant drops in MetSyn across the CRF continuum. The largest declines were from the lowest-fit groups for men and women (≤25th percentile) to the adjacent category (Q2), but the relationship was graded, meaning that moving from Q2 to Q3 and ultimately to the highest-fit group represented a statistically significant decline in risk for MetSyn within our study. These results support our original findings by incorporating a national CRF database into the analytic model. The FRIEND for CRF accounts for the naturally occurring differences in VO~2max~ that occur between sexes and across the age continuum and provides a national database for comparison across studies.

The protective effects of higher VO~2max~ that are shown in the present study represent values that are attainable by most of the general public. Cardiorespiratory fitness values of approximately 22.0 and 29.0 mL/kg per minute for women and men, respectively, which represents the threshold between the lowest VO~2max~ quartile and the second quartile, are reasonably attainable through regular aerobic exercise training. Further reduction in MetSyn was seen in those individuals who were in the 2 upper fitness quartiles. Age did not affect the logistic results for the women in a meaningful way and only modestly affected the results for men. Additional support for the modest effect of age on our results comes from the FRIEND, which categorizes VO~2max~ into sex-age categories. Values for measured VO~2max~ below the 25th percentile (sex- and age-adjusted) in the FRIEND are clearly risky for the presence of MetSyn. Therefore, we suspect that the differences in fitness associated with aging did not impact our results much. Obviously, multiple factors are related to our measure of CRF, but sedentary lifestyle is a major part of the relationship. Most of the adults in the present analysis were sedentary at the time of exercise testing. Further protection from MetSyn would likely be accrued as one moves up the CRF continuum with regular exercise training.

There are several strengths and limitations to the present study. Strengths include a large apparently healthy cohort that was self-referred, measured VO~2max~, and inclusion of the FRIEND in the analysis. To our knowledge, this study represents the largest cohort of adults that has shown this association with MetSyn using VO~2max~ as the measure of CRF. Limitations include that the cohort was approximately 95% percent white and that exercise testing and risk factor assessments took place over a large period of years with only slight modifications in some testing procedures. However, we believe these limitations to be marginal because the laboratory techniques used were similar and consistent with guidelines at the time of testing. What did change over time are the metabolic risk factor *values* that were considered abnormal, and we have used the most recent thresholds for each risk factor in our analyses. In addition, because there was a relatively low prevalence of MetSyn in the highest CRF groups for men and women, caution is warranted in the interpretation of the risk level for these groups. And finally, results from the present study are cross-sectional in nature, so we should be cautious in drawing conclusions about causation.

Conclusion {#sec4}
==========

The present study confirms the association between CRF and MetSyn in men and women and extends it to include CRF as defined by measured VO~2max~. The results of the present study are also strengthened by the FRIEND application, which standardizes VO~2max~ across sex and gender percentiles and are generalizable to the larger population. On the basis of our results, clinicians should first focus on the lowest-fit individuals and encourage them to adopt a more physically active lifestyle, which would improve their VO~2max~. Because our results were graded in nature, individuals should be encouraged to adopt a regular exercise program that contributes to an improvement in VO~2max~ to upper quartiles.
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[^1]: BMI = body mass index; BALL ST= Ball State Adult Fitness Longitudinal Lifestyle Study; DBP = diastolic blood pressure; FRIEND = Fitness Registry and the Importance of Exercise National Database; HDL-C = high-density lipoprotein cholesterol; HR = heart rate; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure; VO~2max~ = maximal oxygen uptake.

[^2]: Values presented as mean ± SD unless otherwise specified. Current cigarette smoking and habitual physical activity as described within Whaley et al.[@bib36] FRIEND percentile referenced from Kaminsky et al.[@bib34]

[^3]: SI conversion units: To convert total cholesterol, LDL-C, and HDL-C values to mmol/L, multiply by 0.0259; to convert triglyceride values to mmol/L, multiply by 0.0113; to convert glucose values to mmol/L, multiply by 0.0555

[^4]: Significant difference between males and females (*P*\<.001).

[^5]: HDL-C = high-density lipoprotein cholesterol.

[^6]: ≥102 cm for men; ≥88 cm for women.

[^7]: ≥100 mg/dL (to convert to mmol/L, multiply by 0.0555) or drug treatment for impaired fasting glucose.

[^8]: ≥130 systolic or 85 diastolic mm Hg; or drug treatment for hypertension.

[^9]: \<40 mg/dL for men; \<50 mg/dL for women, (to convert to mmol/L, multiply by 0.0259), or drug treatment for low HDL-C.

[^10]: ≥150 mg/dL (to convert to mmol/L, multiply by 0.0113) or drug treatment for high serum triglycerides.

[^11]: Those with ≥3 of the risk factors were coded for analyses as having the metabolic syndrome.

[^12]: BMI = body mass index; DBP = diastolic blood pressure; FRIEND = Fitness Registry and the Importance of Exercise National Database; HDL-C = high-density lipoprotein cholesterol; HR = heart rate; LDL-C = low-density lipoprotein cholesterol; MetSyn = metabolic syndrome; SBP = systolic blood pressure; VO~2max~ = maximal oxygen uptake.

[^13]: Values presented as mean ± SD unless otherwise specified. FRIEND percentile referenced from Kaminsky et al.[@bib34]

[^14]: SI conversion units: To convert total cholesterol, LDL-C, and HDL-C values to mmol/L, multiply by 0.0259; to convert triglyceride values to mmol/L, multiply by 0.0113; to convert glucose values to mmol/L, multiply by 0.0555

[^15]: Significant difference between MetSyn and healthy (*P*\<.001).

[^16]: MetSyn = metabolic syndrome; OR = odds ratio.

[^17]: Data for ORs are presented as ORs (CIs).

[^18]: Adjusted for age at test date.

[^19]: Adjusted for age at test date, sex, physical activity, and cigarette smoking.

[^20]: MetSyn = metabolic syndrome; OR = odds ratio; VO2max = maximal oxygen uptake.

[^21]: Data for ORs are presented as ORs (CIs).

[^22]: Adjusted for age at test date, physical activity, and cigarette smoking status.

[^23]: FRIEND = Fitness Registry and the Importance of Exercise National Database; MetSyn = metabolic syndrome.

[^24]: FRIEND percentile referenced from Kaminsky et al.[@bib34]
